Literature DB >> 20020131

Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.

Hiba M Shendi1, Deirdre Walsh, J David M Edgar.   

Abstract

Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflammatory drugs, colchicine, steroids, statins and thalidomide have all been tried. Recently, some patients have demonstrated a good clinical response to either etanercept or anakinra. We report a case of a 10-year-old girl who experienced prolonged and severe inflammatory attacks, when she was treated with etanercept, and later with anakinra.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020131     DOI: 10.1007/s00296-009-1322-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever.

Authors:  F Marchetti; E Barbi; A Tommasini; C Oretti; A Ventura
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

2.  Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.

Authors:  E J Bodar; J C H van der Hilst; J P H Drenth; J W M van der Meer; A Simon
Journal:  Neth J Med       Date:  2005 Jul-Aug       Impact factor: 1.422

3.  Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group.

Authors:  J P Drenth; L Cuisset; G Grateau; C Vasseur; S D van de Velde-Visser; J G de Jong; J S Beckmann; J W van der Meer; M Delpech
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

4.  Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  J P Drenth; A G Vonk; A Simon; R Powell; J W van der Meer
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

5.  Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency.

Authors:  Marco Nevyjel; Alessandra Pontillo; Lorenzo Calligaris; Alberto Tommasini; Andrea D'Osualdo; Hans R Waterham; Marilena Granzotto; Sergio Crovella; Egidio Barbi; Alessandro Ventura
Journal:  Pediatrics       Date:  2007-01-29       Impact factor: 7.124

6.  Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Anna Simon; Elizabeth Drewe; Jos W M van der Meer; Richard J Powell; Richard I Kelley; Anton F H Stalenhoef; Joost P H Drenth
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

7.  Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.

Authors:  Jeroen C H van der Hilst; Evelien J Bodar; Karyl S Barron; Joost Frenkel; Joost P H Drenth; Jos W M van der Meer; Anna Simon
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

8.  Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum.

Authors:  Viola Prietsch; Ertan Mayatepek; Hermann Krastel; Dorothea Haas; Dorothee Zundel; Hans R Waterham; Ronald J A Wanders; K Michael Gibson; Georg F Hoffmann
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

9.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Kazuki Takada; Ivona Aksentijevich; Vijayabhanu Mahadevan; Jane A Dean; Richard I Kelley; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2003-09

10.  Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  J P Drenth; M van Deuren; J van der Ven-Jongekrijg; C G Schalkwijk; J W van der Meer
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

View more
  13 in total

Review 1.  Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.

Authors:  Svetlana Kostjukovits; Liisa Kalliokoski; Kaisu Antila; Matti Korppi
Journal:  Eur J Pediatr       Date:  2015-02-27       Impact factor: 3.183

Review 2.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

Review 3.  Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature.

Authors:  Raquel Campanilho-Marques; Paul A Brogan
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980

4.  Different clinical presentation of the hyperimmunoglobulin D syndrome (HIDS) (four cases from Turkey).

Authors:  Dıdem Arslan Tas; Suzan Dınkcı; Eren Erken
Journal:  Clin Rheumatol       Date:  2012-01-14       Impact factor: 2.980

5.  Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.

Authors:  Claudia Fabiani; Antonio Vitale; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Jurgen Sota; Lorenzo Vannozzi; Gerardo di Scala; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Marco Capozzoli; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2018-04-18       Impact factor: 2.980

Review 6.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 7.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 8.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

Review 9.  Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?

Authors:  C M Mulders-Manders; A Simon
Journal:  Semin Immunopathol       Date:  2015-05-20       Impact factor: 9.623

Review 10.  Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Francesco Caso; Isabella Muscari; Flora Magnotti; Maria Giuseppina Brizi; Susanna Guerrini; Maria Patti; Leonardo Punzi; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.